[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Salvia BioElectronics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100550697","the-reclaim-study-100550697",false,"NCT06450444","The RECLAIM Study.","Randomized, Double-blind, Controlled Trial to Investigate Combined Occipital and Supra-orbital Neuromodulation in Resistant Migraine. The RECLAIM Study.","RECLAIM","Inclusion Criteria:\n\n* Diagnosis of migraine as defined by the ICHD-3 Classification (with or without aura) with a history of chronic or high-frequency episodic migraine for at least 1 year prior to screening\n* Failure of 3 or more preventive pharmacological therapies\n* Stable on preventive migraine treatments\n* Psychologically stable\n\nExclusion Criteria:\n\n* Concomitant invasive or non-invasive neuromodulation\n* Previous exposure to an implantable neuromodulation device for headache\n* Have an existing active implantable medical device nearby the implant location (e.g. DBS, cochlear implant)\n* Use of onabotulinum toxin A injections for the treatment of migraine in the past 3 months.\n* Use of local corticosteroid injections in the occipital or supra-orbital region in the past 3 months prior to enrollment.\n* Not pregnant, nursing or not using contraception","ALL","18 Years","84 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to evaluate the safety and performance, including clinical benefit, of the PRIMUS System for the treatment of Resistant Migraine.",[28,29],"Chronic Migraine","High Frequency Episodic Migraine","RECRUITING","2026-03-26",{"date":33,"type":34},"2026-03-27","ACTUAL",{"date":36,"type":34},"2024-06-24",{"date":38,"type":22},"2029-01-31",{"name":40,"class":41},"Salvia BioElectronics","INDUSTRY",11,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100601667","response-to-combined-trigeminal-and-occipital-nerve-stimulation-for-the-preventive-treatment-in-chronic-cluster-headache-100601667","NCT07113470","Response to Combined Trigeminal and Occipital Nerve Stimulation for the Preventive Treatment in Chronic Cluster Headache","Response to Combined Trigeminal and Occipital Nerve Stimulation for the Preventive Treatment in Chronic Cluster Headache: The RESPONSE-II Study","RESPONSE-II","Inclusion Criteria:\n\n1. Able and willing to provide informed consent\n2. 18 years of age or older\n3. Documented Primary Chronic Cluster Headache, for at least 1 year as per ICHD-3 criteria\n\nExclusion Criteria:\n\n1. Any other chronic primary or secondary headache disorder, unless they can clearly differentiate them from cluster headache attacks based on the quality and associated symptoms\n2. Secondary Cluster Headache",{"count":52,"type":22},10,[25],"This is a limited open-label study being performed at two centers in the Netherlands. All participants will receive the same treatment, and both the patients and doctors will know what that treatment is. The goal is to see how safe and effective the PRIMUS system is for preventing Chronic Cluster Headaches (CCH) in people who haven't responded well to the drug verapamil. The study will also look at the patients' experience using the system.",[56],"Chronic Cluster Headache","2026-03-20",{"date":59,"type":34},"2026-03-25",{"date":61,"type":34},"2026-03-17",{"date":63,"type":22},"2028-12-01",{"name":40,"class":41},1,""]